Literature DB >> 19332671

Bacteriostatic and bactericidal activities of tigecycline against Coxiella burnetii and comparison with those of six other antibiotics.

Ioanna Spyridaki1, Anna Psaroulaki, Iosif Vranakis, Yannis Tselentis, Achilleas Gikas.   

Abstract

The present article is a study of the in vitro susceptibility of eight Greek Coxiella burnetii isolates, derived from patients with acute Q fever, and two reference strains of Coxiella burnetii to tigecycline. The bacteriostatic activity of tigecycline was compared with those of six other antibiotics using a shell vial assay. The MICs of the examined antibiotics were as follows: tigecycline ranged from 0.25 to 0.5 microg/ml; doxycycline, trovafloxacin, and ofloxacin ranged from 1 to 2 microg/ml; linezolid and clarithromycin ranged from 2 to 4 microg/ml; and ciprofloxacin ranged from 4 to 8 microg/ml. Tigecycline was effective in inhibiting the infection of Vero cells by C. burnetii. No bactericidal activity was observed against C. burnetii at 4 microg/ml.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19332671      PMCID: PMC2687195          DOI: 10.1128/AAC.01424-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  In vitro susceptibility to tetracycline and fluoroquinolones of Japanese isolates of Coxiella burnetii.

Authors:  Masako Andoh; Takashi Naganawa; Tsuyoshi Yamaguchi; Hideto Fukushi; Katsuya Hirai
Journal:  Microbiol Immunol       Date:  2004       Impact factor: 1.955

2.  Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis.

Authors:  P Y Levy; M Drancourt; J Etienne; J C Auvergnat; J Beytout; J M Sainty; F Goldstein; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.

Authors:  D Raoult; H Torres; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

5.  Correlation between ratio of serum doxycycline concentration to MIC and rapid decline of antibody levels during treatment of Q fever endocarditis.

Authors:  Jean-Marc Rolain; Areen Boulos; Marie-Noëlle Mallet; Didier Raoult
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Correlation between serum doxycycline concentrations and serologic evolution in patients with Coxiella burnetii endocarditis.

Authors:  J M Rolain; M N Mallet; D Raoult
Journal:  J Infect Dis       Date:  2003-10-13       Impact factor: 5.226

7.  In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; E Scoulica; A Psaroulaki; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 8.  Antibiotic treatment of rickettsiosis, recent advances and current concepts.

Authors:  D Raoult
Journal:  Eur J Epidemiol       Date:  1991-05       Impact factor: 8.082

9.  In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones.

Authors:  M R Yeaman; L A Mitscher; O G Baca
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.

Authors:  Paul H Edelstein; William J Weiss; Martha A C Edelstein
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more
  7 in total

1.  Coxiella burnetii - Pathogenic Agent of Q (Query) Fever.

Authors:  Lutz Gürtler; Ursula Bauerfeind; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Volkmar Schottstedt; Johanna Strobel; Hannelore Willkommen
Journal:  Transfus Med Hemother       Date:  2013-12-23       Impact factor: 3.747

Review 2.  From Q Fever to Coxiella burnetii Infection: a Paradigm Change.

Authors:  Carole Eldin; Cléa Mélenotte; Oleg Mediannikov; Eric Ghigo; Matthieu Million; Sophie Edouard; Jean-Louis Mege; Max Maurin; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Coxiella burnetti prosthetic joint infection in an immunocompromised woman: iterative surgeries, prolonged ofloxacin-rifampin treatment and complex reconstruction were needed for the cure.

Authors:  Patrick Miailhes; Anne Conrad; Chantal Sobas; Frederic Laurent; Sebastien Lustig; Tristan Ferry
Journal:  Arthroplasty       Date:  2021-12-02

Review 4.  Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review.

Authors:  Sajad Yaghoubi; Angelina Olegovna Zekiy; Marcela Krutova; Mehrdad Gholami; Ebrahim Kouhsari; Mohammad Sholeh; Zahra Ghafouri; Farajolah Maleki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-05       Impact factor: 3.267

5.  Does Tigecycline Have a Place in Therapy for Rickettsial Infection of the Central Nervous System?

Authors:  Antonio Mastroianni; Sonia Greco; Filippo Urso; Maria Vittoria Mauro; Valeria Vangeli
Journal:  Infect Chemother       Date:  2022-03

6.  In Vitro Activity of Tigecycline Against Orientia tsutsugamushi.

Authors:  Sun Myoung Lee; Hae Yoon Kwon; Jae Hyoung Im; Ji Hyeon Baek; Seung Sik Hwang; Jae Seung Kang; Moon Hyun Chung; Jin Soo Lee
Journal:  Yonsei Med J       Date:  2016-07       Impact factor: 2.759

7.  Neurotransmitter System-Targeting Drugs Antagonize Growth of the Q Fever Agent, Coxiella burnetii, in Human Cells.

Authors:  Marissa S Fullerton; Punsiri M Colonne; Amanda L Dragan; Katelynn R Brann; Richard C Kurten; Daniel E Voth
Journal:  mSphere       Date:  2021-07-07       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.